IL17A

Overview

IL17A encodes interleukin-17A, a proinflammatory cytokine produced primarily by Th17 cells and other adaptive immune populations. It is a central mediator of mucosal immunity and host defense, but it is also strongly implicated in chronic inflammatory and autoimmune disease. IL-17A acts by promoting the expression of downstream inflammatory mediators, chemokines, and tissue-remodeling factors, thereby amplifying immune-cell recruitment and local inflammation. In recent biomedical literature, IL-17A is repeatedly discussed alongside IFNG, interleukin-6, tumor necrosis factor alpha, nuclear factor kappa B, and related pathways that shape inflammatory signaling.

Clinically, IL-17A is an important biomarker and therapeutic target. Neutralization of IL-17A, alone or together with IL-17F, has been used in inflammatory diseases such as plaque psoriasis, and IL-17A signaling is also being investigated in inflammatory bowel disease, autoimmune hepatitis, arthritis, uveitis, kidney injury, melanoma brain metastases, infectious disease responses, and fibrosis. Because IL-17A sits at the intersection of protective immunity and pathogenic inflammation, it is frequently studied both as a readout of immune activation and as a mechanistic driver of disease.

Focus of Latest Publications

IL-17A has emerged as a key proinflammatory cytokine with substantial therapeutic potential across multiple disease contexts. Bimekizumab, a dual interleukin-17A and IL-17F inhibitor, demonstrated high efficacy and favorable long-term drug survival over 2 years in real-world treatment of moderate-to-severe plaque psoriasis. Secukinumab, a selective IL-17A inhibitor, is being evaluated as additional therapy for giant cell arteritis, a condition where many patients experience glucocorticoid-related toxicity or disease relapse. These monoclonal antibody approaches confirm the clinical relevance of targeting IL-17A in inflammatory and systemic diseases.

IL-17A plays a critical role in neuroinflammatory pathways and immune-mediated thrombosis. In a rat model of cerebral ischemia-reperfusion injury, suppression of IL-17A significantly improved neurological function and reduced infarct volume through modulation of the IL-17A/mitogen-activated protein kinase/NF-κB signaling pathway. In experimental autoimmune encephalomyelitis, an adaptive cellular source of IL-17A and IL-17F was absolutely required for disease induction; loss of IL-17A/F signaling eliminated an IL-23 receptor-driven pathogenic signature in T helper 17 cells. Furthermore, proteomic studies in cancer patients identified IL-17A-driven endothelial activation as a mechanistic link to thrombotic risk; administration of anti-IL-17A antibodies to CD200R1-deficient mice normalized thrombosis markers in vivo, suggesting IL-17A inhibition as a therapeutic strategy to reduce cancer-associated venous thromboembolism.

IL-17A has emerged as both a biomarker and therapeutic target in cancer immunotherapy. In melanoma brain metastases, codelivery of anti-IL-17 and anti-CD73 antibodies via a nose-to-brain delivery platform enhanced anti-tumor immunity by promoting CD8+ T cell activation, proinflammatory macrophage polarization, and reducing regulatory T cell infiltration. In high-risk bladder cancer treated with Bacillus Calmette-Guérin vaccine, IL-17 along with IL-21 and IL-26 were identified as predictive of therapeutic response, with responders characterized by increased Th17-like Th1 cells expressing these proinflammatory cytokines. In patients receiving checkpoint blockade immunotherapy, autoantibodies targeting IL-17 pathway proteins were associated with improved therapeutic response when antibodies possessed neutralizing activity.

IL-17A represents a systemic inflammatory biomarker with broad clinical associations. Serum IL-17A is elevated in periodontitis patients independent of systemic comorbidities, suggesting IL-17A dysregulation links oral inflammation to systemic inflammaging. In diabetic patients, elevated aqueous humor IL-17 levels correlated with diabetes-related ocular complications and microvascular inflammation. In cultured skin fibroblasts exposed to a pro-inflammatory cytokine cocktail including IL-17A, mitochondrial dysfunction and inflammatory metabolic reprogramming were induced; treatment with plant-derived nanovesicles suppressed these IL-17A-associated inflammatory effects and restored mitochondrial respiration. Sex-specific determinants of circulating IL-17A have been identified, with inflammatory mechanisms predominating in males and a potassium-linked metabolic axis in females, indicating that sex influences IL-17A regulation and may have implications for disease susceptibility, biomarker interpretation, and treatment response.

Key Publications

• NEWJun Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy. (Dermatology and therapy, 2026, PMID 42366325): "Bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, has demonstrated high efficacy in clinical trials for moderate-to-severe plaque psoriasis."
• NEWJun Levels of DEL-1 and IL-17 in the aqueous humor of cataract patients with diabetes without diabetic retinopathy. (International ophthalmology, 2026, PMID 42347979): "This study aimed to investigate whether DEL-1 and IL-17 levels in the aqueous humor are elevated in patients with diabetic cataract and to evaluate the potential of these biomarkers for early diagnosis or for monitoring of ocular inflammation."
• NEWJun Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. (Science translational medicine, 2026, PMID 42308329): "CD200R1-deficient mice were characterized by features of a prothrombotic state, with elevated thrombin-antithrombin complexes, increased interleukin-17A (IL-17A), and endothelial inflammation."
• Jun Secukinumab for Giant Cell Arteritis. (NEJM evidence, 2026, PMID 42234457): "Secukinumab, a fully human monoclonal antibody that selectively inhibits interleukin-17A, is being studied as additional therapy for GCA."
• Jun Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to environmental health. (Environment international, 2026, PMID 42235321): "Integrative analyses suggested associations between plasticizer clusters and HF-relevant pathogenic axes, including inflammatory remodeling, metabolic stress, and extracellular matrix processes, with subtype-resolved enrichment patterns consistent with VEGF/MAPK and hormonal signaling in dilated cardiomyopathy (DCM) and TNF/IL-17 and the diabetes-associated AGE-RAGE axis in ischemic cardiomyopathy (ICM)."
• May Sex dictates IL-17A regulation: Inflammatory determinants in males versus a potassium-linked metabolic axis in females. (PloS one, 2026, PMID 42149862): "Interleukin-17A (IL-17A) is a key Th17 cytokine involved in mucosal defense and chronic inflammation and serves as an important biomarker and therapeutic target in autoimmune, cardiovascular, and infectious diseases."
• May Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases. (Science advances, 2026, PMID 42127192): "To overcome these barriers, we developed a nose-to-brain delivery platform using glycerol as a mucosal penetration enhancer to codeliver anti-IL-17 and anti-CD73 antibodies."
• May Humoral contributions to checkpoint blockade therapy. (Journal for immunotherapy of cancer, 2026, PMID 42114949): "Of these, individuals who possessed autoantibodies against one or more proteins in the type-I interferon, interleukin (IL)-6 or IL-17 pathways or to tumor necrosis factor-like ligand 1A (TL1A) tended to have better responses to therapy, especially if the antibodies were neutralizing against their respective targets."
• May Mechanistic insights into the neuroprotective effects of yangyin formula on cerebral ischemia-reperfusion injury via the IL-17A/MAPK/NF-κB signaling pathway. (Journal of molecular histology, 2026, PMID 42101703): "Furthermore, YYF suppressed IL-17A, TNF-α, IL-1β, Caspase-3, p38 MAPK, and NF-κB p65 expression in brain and serum, with effects comparable to IL-17A inhibition."
• Jun Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer. (The Journal of clinical investigation, 2026, PMID 42081487): "Using a machine learning-based approach, we identified that Th17-like Th1 cytokines, such as IL-17, IL-21, and IL-26, are predictive of response, which was subsequently validated in a separate BCG-treated BCa cohort."